SQZ Biotechnologies (NYSE:SQZ) Short Interest Update

SQZ Biotechnologies (NYSE:SQZGet Rating) was the target of a large decline in short interest in May. As of May 31st, there was short interest totalling 1,610,000 shares, a decline of 15.7% from the May 15th total of 1,910,000 shares. Based on an average daily trading volume, of 492,900 shares, the short-interest ratio is presently 3.3 days. Currently, 7.9% of the company’s stock are sold short.

In related news, Director Klavs F. Jensen acquired 14,326 shares of the firm’s stock in a transaction on Wednesday, May 25th. The stock was purchased at an average cost of $3.52 per share, with a total value of $50,427.52. Following the acquisition, the director now owns 353,309 shares of the company’s stock, valued at approximately $1,243,647.68. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 18.00% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. 683 Capital Management LLC lifted its stake in SQZ Biotechnologies by 9.4% in the fourth quarter. 683 Capital Management LLC now owns 1,852,135 shares of the company’s stock valued at $16,540,000 after purchasing an additional 159,748 shares during the last quarter. NanoDimension Inc. purchased a new stake in shares of SQZ Biotechnologies during the fourth quarter worth $12,906,000. BlackRock Inc. lifted its position in shares of SQZ Biotechnologies by 13.1% during the fourth quarter. BlackRock Inc. now owns 1,413,870 shares of the company’s stock worth $12,625,000 after acquiring an additional 163,780 shares in the last quarter. State Street Corp lifted its position in shares of SQZ Biotechnologies by 7.2% during the fourth quarter. State Street Corp now owns 350,617 shares of the company’s stock worth $3,131,000 after acquiring an additional 23,405 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of SQZ Biotechnologies by 17.2% during the fourth quarter. Geode Capital Management LLC now owns 303,500 shares of the company’s stock worth $2,710,000 after acquiring an additional 44,451 shares in the last quarter. Institutional investors and hedge funds own 66.56% of the company’s stock.

Separately, Chardan Capital assumed coverage on SQZ Biotechnologies in a report on Wednesday, May 25th. They issued a “buy” rating and a $17.00 target price for the company.

SQZ Biotechnologies stock traded up $0.10 during trading on Friday, hitting $3.16. The stock had a trading volume of 5,067 shares, compared to its average volume of 153,442. SQZ Biotechnologies has a 1 year low of $2.73 and a 1 year high of $16.17. The stock’s 50 day moving average is $3.54 and its two-hundred day moving average is $6.01.

SQZ Biotechnologies (NYSE:SQZGet Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.06). SQZ Biotechnologies had a negative net margin of 303.43% and a negative return on equity of 57.79%. As a group, equities research analysts forecast that SQZ Biotechnologies will post -2.87 earnings per share for the current fiscal year.

About SQZ Biotechnologies (Get Rating)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

Further Reading

Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.